Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

Y0001112

Gestodene

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(17α)-13-Ethyl-17-hydroxy-18,19-Dinorpregna-4,15-dien-20-yn-3-one, Gestinol, SHB 331, WL 70

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H26O2
CAS Number:
60282-87-3
Molecular Weight:
310.43
MDL number:
MFCD00867858
UNSPSC Code:
41116107
PubChem Substance ID:
329831269
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

gestodene

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C

InChI

1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChI key

SIGSPDASOTUPFS-XUDSTZEESA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Gestodene EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Gestodene is a synthetic progestin used as a contraceptive. Gestodene displays a high binding affinity to the progesterone receptor, and also binds strongly to adrogen and glucocorticoid receptors.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ladakan Jaithitivit et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 95(5), 630-635 (2012-09-22)
To determine cycle control, safety, and acceptability of a 24-day oral contraceptive regimen containing 15 micrograms of ethinylestradiol and 60 micrograms of gestodene. This was an open-label, non-comparative study. Healthy women 18 to 35 years old who attended the Family
Romana Dmitrovic et al.
Obstetrics and gynecology, 119(6), 1143-1150 (2012-05-24)
To estimate whether continuous oral contraceptive pills (OCPs) will result in more pain relief in primary dysmenorrhea patients than cyclic OCPs, which induce withdrawal bleeding with associated pain and symptoms. We conducted a double-blind, randomized, controlled trial comparing continuous to
Sopon Cheewadhanaraks et al.
Gynecologic and obstetric investigation, 74(2), 151-156 (2012-06-23)
To evaluate the efficacy and tolerability of postoperative depot medroxyprogesterone acetate (DMPA) versus postoperative continuous oral contraceptive (OC) pills in the treatment of endometriosis-associated pain. After a conservative surgery, 84 patients with symptomatic endometriosis were randomized to receive either intramuscular
Øjvind Lidegaard et al.
BMJ (Clinical research ed.), 343, d6423-d6423 (2011-10-27)
To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose. National historical registry based cohort study. Four registries in Denmark. Non-pregnant Danish women aged 15-49 with no history of thrombotic
Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
Helen Roberts
Clinical advances in hematology & oncology : H&O, 8(5), 307-309 (2010-06-17)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service